^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PMC-309

    i
    Other names: PMC-309, PMC-309a-z
    Associations

    News

    Trials
    Company:
    PharmAbcine
    Drug class:
    VISTA antagonist
    Related drugs:
    Associations

    News

    Trials
    12ms
    KEYNOTE-E80: Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (clinicaltrials.gov)
    P1, N=67, Not yet recruiting, PharmAbcine | Phase classification: P1a/1b --> P1
    Phase classification • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • PMC-309
    1year
    KEYNOTE-E80: Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (clinicaltrials.gov)
    P1a/1b, N=67, Not yet recruiting, PharmAbcine | Initiation date: Aug 2023 --> Nov 2023
    Trial initiation date • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • PMC-309
    over1year
    KEYNOTE-E80: Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (clinicaltrials.gov)
    P1a/1b, N=67, Not yet recruiting, PharmAbcine
    New P1 trial • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • PMC-309